A tubular extracellular matrix fiber scaffold and its preparation method and application
Through the combined technology of 3D printing and braiding, a tubular extracellular matrix fiber scaffold with high efficiency anticoagulation performance was prepared, which solved the thrombus and patency rate of small-diameter artificial blood vessels in clinical applications, and achieved the low-cost scale of fiber scaffolds Chemical production, suitable for repair of various tissues.
Patent Information
- Application Number
- CN202410576362.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-10
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-05-10
AI Technical Summary
In clinical applications, existing small-diameter artificial blood vessels have problems such as thrombosis, endometrial hyperplasia and low long-term patency rates. Moreover, the preparation process of traditional extracellular matrix fiber scaffolds is complex and costly, making it difficult to achieve large-scale production.
Tube-shaped extracellular matrix fiber scaffolds were prepared by 3D printing combined with braiding method. Long fibers were obtained through rotary cutting and anticoagulation modification. Dopamine and hirudin were used to improve anticoagulation performance, and high-efficiency and low-cost preparation of fiber scaffolds were achieved.
A tubular extracellular matrix fiber scaffold with good mechanical properties and biological activity was obtained, which can promote endogenous regeneration of tissues, improve blood compatibility and long-term patency, and is suitable for the repair and regeneration of various types of tubular tissues.
Smart Images

Figure CN118512659B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical materials, and in particular relates to a tubular extracellular matrix fiber scaffold and a preparation method and application thereof. Background Art
[0002] Cardiovascular disease (CVD) is the number one killer of human health, and the annual incidence and mortality rates remain high worldwide. The "China Cardiovascular Health and Disease Report 2022" points out: The incidence of CVD in China continues to rise. It is estimated that there are 330 million people suffering from CVD, including 11.39 million people with coronary heart disease and 45.3 million people with peripheral artery disease. Small-caliber artificial blood vessels are an important means of treating coronary and peripheral artery blockages. The global annual demand is more than 3 million, and China's demand accounts for 22%. Clinically, doctors will give priority to using the patient's own blood vessels such as the great saphenous vein, internal mammary artery, radial artery, etc. to replace blocked blood vessels. However, the autologous blood vessels of patients with underlying diseases or who have already used them cannot be used. In addition, the extraction of autologous blood vessels requires secondary surgery and expensive costs, which limits its clinical application. At present, the large-caliber artificial blood vessels used in clinical practice are mainly made of non-degradable expanded polytetrafluoroethylene, polyethylene terephthalate and polyurethane. Although they have shown a high patency rate in large-caliber (inner diameter>6mm) blood vessel transplantation, they are prone to thrombosis, intimal hyperplasia, and low long-term patency rate in small-caliber (inner diameter<6mm) replacement. So far, there are no small-caliber artificial blood vessels (caliber<6mm) with excellent performance in clinical practice. Therefore, the research and development of new small-caliber artificial blood vessels is of great clinical significance.
[0003] In recent years, scientists have constructed a variety of small-caliber artificial blood vessels using synthetic degradable polymer materials or natural materials, hoping to recruit endogenous cells in the body to regenerate in situ into natural vascular tissue. However, although synthetic materials have strong mechanics and good processability, they lack biocompatibility and activity. Although natural materials such as collagen have good biocompatibility, their mechanical properties are weak. The extracellular matrix materials obtained by decellularization have immunomodulatory effects and can provide a regenerative microenvironment for cell adhesion, proliferation and differentiation. Substantial progress has also been made in the construction and application of extracellular matrix artificial blood vessels. The small-caliber artificial blood vessels constructed by decellularization of human or animal arteries have a dense structure, which can limit cell migration and hinder vascular regeneration. The small-caliber artificial blood vessels constructed by extracellular matrix through in vitro cell culture have shown good application prospects. A typical example is that the research group of Professor Laura E. Niklason of Yale University in the United States constructed extracellular matrix artificial blood vessels in vitro using a bioreactor for flow culture. It has shown good anti-infection and angiogenesis performance in arteriovenous fistula models and peripheral artery bypass grafting (JH Lawson, LE Niklason, P. Roy-Chaudhury, Challenges and novel therapies for vascular access in haemodialysis, Nat Rev Nephrol. 16 (2020) 586–602.). However, the culture conditions of this process are harsh, time-consuming, costly and expensive. In contrast, Professor Nicolas L'Heureux and others from the University of Bordeaux in France decellularized the amniotic membrane tissue and cut it into fibers, and further constructed small-caliber artificial blood vessels by weaving. The advantages of this textile process are short time, low cost and strong controllability. However, the limited size of the amniotic membrane results in a limited length of the cut fibers, which makes it difficult to achieve continuous weaving, limiting the large-scale production of braided blood vessels. Wang Guifa cuts the casings into pieces of uniform width with a knife, and then uses them to prepare sutures after degreasing, washing, and twisting. The length of the sutures can reach 40 meters, but this length is still not enough to produce large-size scaffold materials for repairing tissue defects in the human body. Therefore, developing appropriate strategies and processes to prepare extracellular matrix fibers and then weave them into extracellular matrix artificial blood vessels is expected to solve many problems faced in the production of existing extracellular matrix artificial blood vessels.
[0004] In terms of the construction of tubular fiber scaffolds, current methods include double-layer woven fabrics and integrated weaving, which are mature in chemical fiber weaving. However, during the weaving process, the fibers will be repeatedly rubbed, which requires high strength and wear resistance, and the process is relatively complicated, which limits the application of extracellular matrix fibers. Summary of the invention
[0005] In order to solve the above technical problems, the present invention proposes a tubular extracellular matrix fiber scaffold for tissue repair and a preparation method and application thereof.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] A method for preparing a tubular extracellular matrix fiber scaffold comprises preparing the tubular extracellular matrix fiber scaffold by combining 3D printing with a weaving method and then performing anticoagulant modification to obtain the tubular extracellular matrix fiber scaffold.
[0008] Preferably, the method of combining 3D printing with weaving specifically comprises the following steps:
[0009] The decellularized animal tubular tissue is cut by rotary cutting and then twisted, and then the warp part is woven after the weft part is 3D printed to obtain the tubular extracellular matrix fiber scaffold.
[0010] Beneficial effects: The present invention combines the activity of extracellular matrix fibers, the diversity of 3D printing and the unique structural advantages of fabrics.
[0011] More preferably, the microscopic woven structure of the tubular extracellular matrix fiber scaffold is formed by interweaving and interlocking the warp and weft to form one of plain weave, twill weave and satin weave.
[0012] Preferably, the animal tubular tissue is one of a small intestine, a large intestine, an artery and a vein;
[0013] The animals include one or any combination of pigs, cattle, sheep, dogs, horses, mice and rabbits.
[0014] Beneficial effects: The extracellular matrix fibers in the present invention are obtained by rotary cutting, are applicable to various tubular tissues of various animals, and have relatively wide sources of raw materials.
[0015] Preferably, the rotary cutting method comprises the following steps:
[0016] The decellularized animal tubular tissue is placed on a cylindrical mold and fixed on a rotary cutting device, and then cut with a knife or laser in a spiral trajectory to obtain continuous extracellular matrix strips.
[0017] Beneficial effect: Compared with the traditional longitudinal direct cutting, the rotary cutting method selected in the present invention can obtain extracellular matrix fibers several times longer than their own length, and then weave a longer tubular extracellular matrix fiber scaffold.
[0018] Preferably, the 3D printing of the weft part and then weaving the warp part specifically comprises the following steps:
[0019] The weaving structure of the scaffold material is designed according to the required macroscopic shape, and the corresponding G code is written. The extracellular matrix fibers are printed on a platform with regularly arranged needle tubes inserted to weave the weft part of the scaffold material. The needle tubes are replaced with extracellular matrix fibers to weave the warp part of the scaffold material.
[0020] Beneficial effects: The traditional weaving process is complicated. The present invention combines 3D printing and weaving to finely construct tubular fabrics.
[0021] Preferably, the anticoagulant modification comprises the following steps:
[0022] The tubular extracellular matrix fiber scaffold is immersed in a dopamine solution and stirred for reaction, and then placed in a hirudin solution and stirred for reaction, thereby completing the anticoagulant modification.
[0023] Preferably, the concentration of the dopamine solution is 0.1-10%;
[0024] The concentration of the hirudin solution is 0.5-10%.
[0025] Beneficial effects: Hirudin has excellent anticoagulant properties and can inhibit thrombin activity. Dopamine can chemically react with multiple groups, thereby binding the anticoagulant to the surface of the tubular fabric and improving its anticoagulant properties.
[0026] A method for preparing a tubular extracellular matrix fiber scaffold prepares a tubular extracellular matrix fiber scaffold, wherein the tubular extracellular matrix fiber scaffold has a diameter of 1-100 mm and a length of 1-800 mm.
[0027] Beneficial effects: The present invention adopts 3D printing combined with weaving, which can flexibly control the diameter and length of the woven tubular stent.
[0028] The invention discloses an application of a tubular extracellular matrix fiber scaffold in preparing a tissue repair scaffold material.
[0029] Preferably, the tissue repair includes repair of blood vessels, nerves, tendons, trachea, esophagus, large intestine or small intestine.
[0030] Beneficial effects: The extracellular matrix fiber tubular scaffold obtained by the present invention has good mechanical properties and biological activity, and can be applied to the repair and regeneration of various types of tubular tissues.
[0031] Compared with the prior art, the present invention has the following advantages and technical effects:
[0032] The present invention utilizes 3D printing technology to assist weaving technology, and can prepare sufficiently long extracellular matrix fiber scaffolds, and can also finely control the structure of tubular extracellular matrix fiber scaffolds. Compared with traditional decellularized matrix scaffold materials, the tubular extracellular matrix fiber scaffold obtained by the present invention can induce rapid migration of cells, promote endogenous regeneration of tissues, and degradation of extracellular matrix fibers can release a variety of active factors to accelerate tissue repair, and can achieve efficient and low-cost large-scale preparation of extracellular matrix tubular materials. In addition, the present invention modifies the tubular extracellular matrix fiber scaffold with anticoagulant drug hirudin through dopamine, and the anticoagulant drug hirudin is modified with dopamine to make the tubular material have persistent anticoagulant activity, which can inhibit platelet adhesion activity, improve blood compatibility, promote intimal regeneration, and improve long-term patency. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The drawings constituting a part of the present application are used to provide a further understanding of the present application. The illustrative embodiments and descriptions of the present application are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:
[0034] Figure 1 Example 2: Preparation and performance characterization of extracellular matrix fibers;
[0035] Among them, A is a schematic diagram of the decellularization of animal tubular tissue, B is a diagram of the rotary cutting mode of tubular tissue, C is a diagram of the twisting mode of tubular tissue strips, D is the decellularized fiber of the small intestinal submucosa and a schematic diagram, E is the hematoxylin and eosin staining and cell nucleus staining after decellularization of the small intestinal submucosa, F is the extracellular matrix strips of different widths obtained after rotary cutting, and G is the extracellular matrix fiber morphology obtained after twisting at different speeds;
[0036] Figure 2 The preparation and characterization of the extracellular matrix fiber braided artificial blood vessel in Example 2;
[0037] Wherein, A is a schematic diagram of the structure of an artificial blood vessel woven with extracellular matrix fibers; B and C are a side view and a top view of an artificial blood vessel woven with extracellular matrix fibers; D is a long artificial blood vessel woven with extracellular matrix fibers;
[0038] Figure 3 The anticoagulant modification of the extracellular matrix fiber braided artificial blood vessel of Example 3;
[0039] Among them, A is the platelet adhesion diagram of the artificial blood vessels woven with extracellular matrix fibers and modified with or without hirudin, and B is the APTT, PT, and TT of the artificial blood vessels woven with or without hirudin;
[0040] Figure 4 Example 3: Extracellular matrix fiber braided artificial blood vessel used for rat abdominal aorta replacement and effect evaluation;
[0041] Among them, A is the patency of modified and unmodified hirudin tubular stents detected by color Doppler ultrasound in rat abdominal aorta replacement one month after surgery, and B is the morphology of modified and unmodified hirudin tubular stents one month after surgery. DETAILED DESCRIPTION
[0042] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0043] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0044] The embodiment of the present invention discloses a method for preparing a tubular extracellular matrix fiber scaffold. The tubular extracellular matrix fiber scaffold is prepared by combining 3D printing with a weaving method, and then anticoagulant modification is performed to obtain the tubular extracellular matrix fiber scaffold.
[0045] In a preferred embodiment, the method of combining 3D printing with weaving specifically includes the following steps:
[0046] The decellularized animal tubular tissue is cut by rotary cutting and then twisted, and then the warp part is woven after the weft part is 3D printed to obtain the tubular extracellular matrix fiber scaffold.
[0047] In a more preferred embodiment, the microscopic woven structure of the tubular extracellular matrix fiber scaffold is interwoven and interlocked by warp and weft to form one of plain weave, twill weave and satin weave.
[0048] In a preferred embodiment, the animal tubular tissue is one of a small intestine, a large intestine, an artery and a vein;
[0049] The animals include one or any combination of pigs, cattle, sheep, dogs, horses, mice and rabbits.
[0050] In a preferred embodiment, the rotary cutting method comprises the following steps:
[0051] The decellularized animal tubular tissue is placed on a cylindrical mold and fixed to a rotary cutting device, and then cut with a knife or laser in a spiral trajectory to obtain a continuous extracellular matrix strip. The rotary cutting method of the present invention can make the width of the extracellular matrix strip controllable.
[0052] In a preferred embodiment, the 3D printing of the weft portion and then the weaving of the warp portion specifically comprises the following steps:
[0053] The weaving structure of the scaffold material is designed according to the required macroscopic shape, and the corresponding G code is written. The extracellular matrix fibers are printed on a platform with regularly arranged needle tubes inserted to weave the weft part of the scaffold material. The needle tubes are replaced with extracellular matrix fibers to weave the warp part of the scaffold material.
[0054] In a preferred embodiment, the anticoagulant modification comprises the following steps:
[0055] The tubular extracellular matrix fiber scaffold is immersed in a dopamine solution and stirred for reaction, and then placed in a hirudin solution and stirred for reaction, thereby completing the anticoagulant modification.
[0056] In a preferred embodiment, the concentration of the dopamine solution is 0.1-10%;
[0057] The concentration of the hirudin solution is 0.5-10%.
[0058] More preferably, the stirring reaction time is 24 hours, and the continued stirring reaction time is 2 hours.
[0059] The embodiment of the present invention also discloses a method for preparing a tubular extracellular matrix fiber scaffold to prepare the tubular extracellular matrix fiber scaffold, wherein the tubular extracellular matrix fiber scaffold has a diameter of 1-100 mm and a length of 1-800 mm.
[0060] The embodiment of the present invention also discloses the use of a tubular extracellular matrix fiber scaffold in preparing a tissue repair scaffold material.
[0061] In a preferred embodiment, the tissue repair includes repair of blood vessels, nerves, tendons, trachea, esophagus, large intestine or small intestine.
[0062] Unless otherwise specified, the tubular tissues in the embodiments of the present invention were purchased;
[0063] Among them, bovine carotid artery, porcine small intestinal mucosa and porcine abdominal aorta were purchased from a slaughterhouse (Tianjin Ershang Yingbin Meat Food Co., Ltd.).
[0064] Unless otherwise specified, the room temperature in the embodiments of the present invention refers to 25±3°C.
[0065] The operation process of 3D printing in the following embodiments can be carried out according to the requirements of the equipment manual, and the G code design of the structural design is also carried out according to the structural requirements of the final product. They are all conventional operation processes and are well known to those skilled in the art.
[0066] Example 1
[0067] A method for preparing a tubular bovine carotid artery extracellular matrix fiber scaffold for tissue repair comprises the following steps:
[0068] (1) Decellularization: The whole or part of the bovine carotid artery tissue was placed in a 0.1% peracetic acid solution at a mass ratio of 1:5 between tissue and solution, and stirred at 50 r / min for 2 hours for disinfection. After disinfection, it was taken out and rinsed with water three times, and placed in a 1% sodium dodecyl sulfate solution at a mass ratio of 1:5 between tissue and solution, stirred and washed at a stirring rate of 50 r / min, and the solution was changed every 6 hours for 1 day. Then, it was washed with water at a mass ratio of 1:5 between tissue and water, stirred and washed at a stirring rate of 50 r / min, and the solution was changed every 5 hours for 3 days. After washing, the tissue and solution were washed with Tris-HCL solution containing DNA and RNA enzymes (50 units / mL DNA enzyme + 1 unit / mL RNA enzyme) at a mass ratio of 1:5, and enzyme-washed at 50 r / min and 37°C for 20 hours, taken out, and washed with water for 3 days to obtain decellularized tubular tissue.
[0069] (2) Peeling: The above-mentioned decellularized tubular tissue was put on a metal rod, and then the metal rod was fixed to the peeling equipment. The surface of the rod was peeled with a tool in a spiral trajectory. The metal rod rotation speed was set to 80 r / min and the tool lateral movement speed was set to 50 mm / min. Peeling obtained a continuous strip with a width of 3.5 mm.
[0070] (3) Twisting: The extracellular matrix strips were twisted into fibers using a twisting and winding device and automatically wound onto a bobbin. The twisting speed was 90 r / min, the winding speed was 110 r / min, and the twisting degree was 3 r / cm.
[0071] (4) Structural design: Design the fiber weaving structure according to the required tubular structure and write the G code for 3D printer operation.
[0072] (5) Printing the weft portion: The extracellular matrix scaffold material was woven using a 3D printing device. The printing platform consisted of a group of vertically inserted needles with a diameter of 21G and a length of 10 cm, forming a square array with a spacing of 1.5 mm. The extracellular matrix fibers were drawn out from the printer nozzle and wound around the needles of the printing platform according to the path controlled by the written G code, and then wound layer by layer to form the weft portion of the scaffold material.
[0073] (6) Weaving the warp part: Pull the needle tube out of the wound scaffold material, and connect each row of wefts in an S-shape along the vacant part of the needle tube with extracellular matrix fibers to form the warp of the scaffold material. Finally, a tubular extracellular matrix fiber scaffold material is obtained. The diameter of the tubular extracellular matrix fiber scaffold material is 5 mm and the length is 30 mm.
[0074] (7) Anticoagulant modification: The tubular stent was immersed in a dopamine solution with a mass concentration of 1% and stirred for reaction for 24 hours. The stent was taken out and placed in a hirudin solution with a mass concentration of 10% and stirred for reaction for 2 hours for anticoagulant modification, thereby obtaining a tubular bovine carotid artery extracellular matrix fiber scaffold for tissue repair.
[0075] Example 2
[0076] A method for preparing a tubular porcine small intestinal submucosal extracellular matrix fiber scaffold for tissue repair comprises the following steps:
[0077] (1) Decellularization: The whole or part of the submucosal layer of the small intestine of the pig is placed in a peracetic acid solution with a mass concentration of 0.1% according to a mass ratio of tissue to solution of 1:5, and stirred at a rate of 50r / min for 2h for disinfection. After disinfection, it is taken out and rinsed with water three times, and placed in a sodium dodecyl sulfate solution with a mass concentration of 1% according to a mass ratio of tissue to solution of 1:5, stirred and washed at a stirring rate of 50r / min, and the solution is changed every 6h for 1 day. Then, it is washed with water at a mass ratio of tissue to water of 1:5, stirred and washed at a stirring rate of 50r / min, and the solution is changed every 5h for 3 days. After washing, the tissue and solution are again washed with Tris-HCL solution containing DNA and RNA enzymes (50 units / mL DNA enzyme + 1 unit / mL RNA enzyme) at a mass ratio of 1:5, and enzyme-washed at 50r / min and 37°C for 20h, taken out, and washed with water for 3 days to obtain decellularized tubular tissue.
[0078] (2) Peeling: The above-mentioned decellularized tubular tissue was put on a metal rod, and then the metal rod was fixed to the peeling equipment. The surface of the rod was peeled with a tool in a spiral trajectory. The metal rod rotation speed was set to 80 r / min and the tool lateral movement speed was set to 50 mm / min. Peeling obtained a continuous strip with a width of 3.5 mm.
[0079] (3) Twisting: The extracellular matrix strips were twisted into fibers using a twisting and winding device and automatically wound onto a bobbin. The twisting speed was 90 r / min, the winding speed was 110 r / min, and the twisting degree was 3 r / cm.
[0080] (4) Structural design: Design the fiber weaving structure according to the required tubular structure and write the G code for 3D printer operation.
[0081] (5) Printing the weft portion: The extracellular matrix scaffold material was woven using a 3D printing device. The printing platform consisted of a group of vertically inserted needles with a diameter of 21G and a length of 10 cm, forming a square array with a spacing of 1.5 mm. The extracellular matrix fibers were drawn out from the printer nozzle and wound around the needles of the printing platform according to the path controlled by the written G code, and then wound layer by layer to form the weft portion of the scaffold material.
[0082] (6) Weaving the warp part: Pull the needle tube out of the wound scaffold material, and connect each row of wefts in an S-shape along the vacant part of the needle tube with extracellular matrix fibers to form the warp of the scaffold material. Finally, a tubular extracellular matrix fiber scaffold material is obtained. The diameter of the tubular extracellular matrix fiber scaffold material is 2 mm and the length is 20 mm.
[0083] Figure 1 It is the preparation and performance characterization of extracellular matrix fibers. It can be seen that after rotary cutting, the extracellular matrix strips are obtained in the present embodiment, and the width is controllable, and the width can reach 1 mm, and the length is super long. 20 cm of decellularized small intestine are rotary cut to 2 mm width, and 8 meters of strips can be obtained, which is much longer than the length of traditional direct cutting. At the same time, the present invention utilizes rotary cutting pure physical processing mode, does not change the material thickness, and does not have acid soluble enzymolysis and wet spinning and other treatments, and will not destroy its activity. In addition, the extracellular matrix fiber fibers after twisting of the present invention are naturally curled, and grooves are formed along the length direction, which can guide orientation regeneration, and the degree of twisting is controllable, and the greater the twist, the tighter the fiber curling.
[0084] Figure 2 This is the preparation and characterization of the extracellular matrix fiber braided artificial blood vessel in Example 2. It can be seen that the extracellular matrix fiber braided artificial blood vessel is a woven structure in terms of weaving structure, which is an interweaving of warp and weft. The warp and weft of the artificial blood vessel are tightly interwoven, and the diameter and length are flexibly controllable.
[0085] (7) Anticoagulant modification: The tubular scaffold was immersed in a dopamine solution with a mass concentration of 1% and stirred for reaction for 24 hours. The scaffold was taken out and placed in a hirudin solution with a mass concentration of 10% and stirred for reaction for 2 hours for anticoagulant modification, thereby obtaining a tubular porcine small intestinal submucosal extracellular matrix fiber scaffold for tissue repair.
[0086] Example 3
[0087] A method for preparing a tubular porcine abdominal aorta extracellular matrix fiber scaffold for tissue repair comprises the following steps:
[0088] (1) Decellularization: The whole or part of the pig abdominal aorta tissue was placed in a 0.1% peracetic acid solution at a mass ratio of 1:5 between tissue and solution, and stirred at 50 r / min for 2 hours for disinfection. After disinfection, it was taken out and rinsed three times with water, and placed in a 1% sodium dodecyl sulfate solution at a mass ratio of 1:5 between tissue and solution, and stirred and washed at a stirring rate of 50 r / min, changing the solution every 6 hours for 1 day. Then, it was washed with water at a mass ratio of 1:5 between tissue and water, and stirred and washed at a stirring rate of 50 r / min, changing the solution every 5 hours for 3 days. After washing, the tissue and solution were washed with Tris-HCL solution containing DNA and RNA enzymes (50 units / mL DNA enzyme + 1 unit / mL RNA enzyme) at a mass ratio of 1:5, and enzyme-washed at 50 r / min and 37°C for 20 hours, taken out, and washed with water for 3 days to obtain decellularized tubular tissue.
[0089] (2) Peeling: The above-mentioned decellularized tubular tissue was put on a metal rod, and then the metal rod was fixed to the peeling equipment. The surface of the rod was peeled with a tool in a spiral trajectory. The metal rod rotation speed was set to 80 r / min and the tool lateral movement speed was set to 50 mm / min. Peeling obtained a continuous strip with a width of 3.5 mm.
[0090] (3) Twisting: The extracellular matrix strips were twisted into fibers using a twisting and winding device and automatically wound onto a bobbin. The twisting speed was 90 r / min, the winding speed was 110 r / min, and the twisting degree was 3 r / cm.
[0091] (4) Structural design: Design the fiber weaving structure according to the required tubular structure and write the G code for 3D printer operation.
[0092] (5) Printing the weft portion: The extracellular matrix scaffold material was woven using a 3D printing device. The printing platform consisted of a group of vertically inserted needles with a diameter of 21G and a length of 10 cm, forming a square array with a spacing of 1.5 mm. The extracellular matrix fibers were drawn out from the printer nozzle and wound around the needles of the printing platform according to the path controlled by the written G code, and then wound layer by layer to form the weft portion of the scaffold material.
[0093] (6) Weaving the warp part: Pull the needle tube out of the wound scaffold material, and connect each row of wefts in an S-shape along the vacant part of the needle tube with extracellular matrix fibers to form the warp of the scaffold material. Finally, a tubular extracellular matrix fiber scaffold material is obtained. The diameter of the tubular extracellular matrix fiber scaffold material is 10 mm and the length is 50 mm.
[0094] (7) Anticoagulant modification: The tubular stent was immersed in a dopamine solution with a mass concentration of 1% and stirred for reaction for 24 hours. The stent was taken out and placed in a hirudin solution with a mass concentration of 10% and stirred for reaction for 2 hours for anticoagulant modification, thereby obtaining a tubular porcine abdominal aorta extracellular matrix fiber scaffold for tissue repair.
[0095] Technical effect:
[0096] 1. Platelet adhesion assay:
[0097] Fresh rabbit blood was centrifuged at 1500r / min for 15min, and the supernatant was taken to obtain platelet-rich plasma (PRP). The platelet concentration was counted using a blood cell counting plate for later use. The tubular extracellular matrix fiber scaffold obtained in Example 3 was cut into 1 cm long and wide sterilized and placed in a 48-well plate. 1mL PBS was added to each well / tube and placed in an incubator for 1h, and then the PBS was removed. 1mL of PRP solution containing 5×105 platelets diluted with PBS was added to each well, and the platelets were placed at 37°C for 3h. The solution after the platelets adhered was removed, rinsed with PBS, and fixed with 2.5% glutaraldehyde for 12h. Then, it was soaked in 25%, 50%, 75%, and 100% ethanol for 30min gradient dehydration, and finally attached to the electron microscope table. After gold spraying, the platelet adhesion morphology was observed by SEM.
[0098] 2. Coagulation time test:
[0099] Fresh rabbit blood was centrifuged at 3000r / min for 15min, and the supernatant was obtained to obtain platelet-poor plasma (PPP). The activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT) and FIB content were tested. The tubular extracellular matrix fiber scaffold obtained in Example 3 was cut into discs and added to centrifuge tubes. 200μL of PPP was added to each tube and incubated at 37°C for 10min. Then, the following were added: (1) 200μL of preheated prothrombin reagent to test PT; (2) 200μL of preheated thrombin reagent to test TT; (3) 200μL of activated partial thromboplastin reagent was added first, incubated at 37°C for 3min, and then 200μL of preheated 1% concentration CaCl2 solution was added to test APTT. The samples obtained by the above three methods were read for coagulation time on a semi-automatic coagulation analyzer.
[0100] The results are as follows Figure 3 As shown by Figure 3 It can be seen that after hirudin grafting, the anticoagulant performance of the tubular extracellular matrix fiber scaffold material was significantly improved, the platelet adhesion was significantly less than that of the unmodified group, there were basically no platelets on the surface of the fabric after grafting, and the APTT, PT, and TT were significantly prolonged after hirudin grafting, especially the APTT, which was prolonged by nearly doubled.
[0101] 3. The tubular extracellular matrix fiber scaffold was used in a rat abdominal aorta replacement experiment, including the following steps:
[0102] Rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (3.3 mL / kg body weight). After the rats entered deep anesthesia, heparin (100 U.I / kg dosage) was injected into the rat tail vein for systemic heparinization. The abdominal hair was shaved, the abdominal skin and muscles were cut open, the infrarenal abdominal aorta was stripped, the arterial small branches were ligated, the two ends of the artery were clamped with an artery clamp, the artery was cut from the middle, and after stripping the outer layer of the artery, the tubular extracellular matrix fiber scaffold obtained in Example 3 was implanted in situ using an end-to-end anastomosis with a 9-0 nylon suture with a needle. The suture was sutured with a rice character method, 8 stitches at each end. After both ends were sutured, cotton was carefully pressed to stop bleeding, and the artery clamp was slowly removed to restore blood flow. The abdominal cavity was flushed with gentamicin sulfate, the muscle layer and skin were sutured with a 3-0 suture, and iodine was disinfected. After anesthesia with isoflurane gas at the 12-week time point, high-resolution ultrasound Doppler was used to detect patency, and then deep anesthesia was performed to obtain samples for inner surface morphology observation.
[0103] Depend on Figure 4 It can be seen that Doppler ultrasound showed that the tubular extracellular matrix fiber scaffold implanted in the rat abdominal aorta was completely unobstructed, without stenosis and aneurysm, while the tubular extracellular matrix fiber scaffold without hirudin grafting was easily blocked. In addition, according to the longitudinal inner surface observation, it can be seen that the inner surface of the tubular extracellular matrix fiber scaffold grafted with hirudin is completely covered with new intimal tissue, without thrombus on the surface, and the suture regeneration is good without obvious stenosis, while the tubular extracellular matrix fiber scaffold group without hirudin grafting has thrombus on the intimal surface.
[0104] The above are only preferred specific implementations of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed in the present application should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.
Claims
1. A method for preparing a tubular extracellular matrix fiber scaffold, characterized in that: The tubular extracellular matrix fiber scaffold is prepared by using 3D printing combined with a weaving method and then subjected to anticoagulant modification to obtain the tubular extracellular matrix fiber scaffold; The method of combining 3D printing with weaving specifically comprises the following steps: The decellularized animal tubular tissue is cut by rotary cutting and then twisted, and then the warp part is woven after the weft part is 3D printed to obtain the tubular extracellular matrix fiber scaffold; The 3D printing of the weft part and then weaving the warp part specifically includes the following steps: The weaving structure of the scaffold material is designed according to the required macroscopic shape, and the corresponding G code is written. The extracellular matrix fibers are printed on a platform with regularly arranged needle tubes inserted to weave the weft part of the scaffold material. The needle tubes are replaced with extracellular matrix fibers to weave the warp part of the scaffold material.
2. The method for preparing a tubular extracellular matrix fiber scaffold according to claim 1, characterized in that: The animal tubular tissue is one of a small intestine, a large intestine, an artery and a vein; The animals include one or any combination of pigs, cattle, sheep, dogs, horses, mice and rabbits.
3. The method for preparing a tubular extracellular matrix fiber scaffold according to claim 1, characterized in that: The rotary cutting method comprises the following steps: The decellularized animal tubular tissue is placed on a cylindrical mold and fixed on a rotary cutting device, and then cut with a knife or laser in a spiral trajectory to obtain continuous extracellular matrix strips.
4. The method for preparing a tubular extracellular matrix fiber scaffold according to claim 1, characterized in that: The anticoagulant modification comprises the following steps: The tubular extracellular matrix fiber scaffold is immersed in a dopamine solution and stirred for reaction, and then placed in a hirudin solution and stirred for reaction, thereby completing the anticoagulant modification.
5. The method for preparing a tubular extracellular matrix fiber scaffold according to claim 4, characterized in that: The concentration of the dopamine solution is 0.1-10%; The concentration of the hirudin solution is 0.5-10%.
6. The tubular extracellular matrix fiber scaffold prepared by the method for preparing a tubular extracellular matrix fiber scaffold according to any one of claims 1 to 5, characterized in that: The tubular extracellular matrix fiber scaffold has a diameter of 1-100 mm and a length of 1-800 mm.
7. Use of the tubular extracellular matrix fiber scaffold as claimed in claim 6 in preparing tissue repair scaffold materials.
8. The use according to claim 7, characterized in that: The tissue repair includes repair of blood vessels, nerves, tendons, trachea, esophagus, large intestine or small intestine.
